CIK: 0001395064
Total reported value
$16.4M
Reporting period: 2025-09-30 · Number of holdings: 9
TAKEDA PHARMACEUTICAL CO LTD disclosed 9 holdings in its latest 13F filing for the period ending 2025-09-30, with total reported value of $16.4M and a quarterly turnover rate of 100.0%.
Browse other institutions with under $100M AUMBrowse other institutions starting with "T"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add OVID
0.0% -$2.3B
Add EQ
0.0% -$709.1M
Add STTK
0.0% -$488.6M
Add LYEL
+33.3% -$442.1M
Add 98422T100
0.0% -$1.1B
Trim RANI
0.0% -$255.9M
Showing top 8 holdings (of 9 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | OVID | Ovid Therapeutics INC | Stock-Other | 59.82% | +45.31% | — | |
| 2 | EQ | Equillium INC | Stock-Other | 15.94% | +11.54% | — | |
| 3 | ✓ | Xilio Therapeutics INC | Stock-Other | 7.59% | +0.99% | — | |
| 4 | STTK | Shattuck Labs INC | Stock-Other | 7.53% | +4.51% | — | |
| 5 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 5.45% | +2.71% | +33.33% | |
| 6 | AMWL | American Well Corp-class A | Stock-Other | 2.92% | -0.86% | — | |
| 7 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.62% | -0.96% | — | |
| 8 | LAB | Standard Biotools INC | Stock-Other | 0.13% | +0.02% | — |
Performance for Q3 2026
—
Performance Last 4 Quarters
—
Based on 0 months of available history
Based on 33% of reported portfolio value with available pricing
Not enough sector-mapped data yet
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2025-09-30 | 9 | $16.4M | 100 | |
| 2025-06-30 | 12 | $19.6M | 0 | |
| 2025-03-31 | 12 | $16.2M | 0 | |
| 2024-12-31 | 12 | $26.6M | 0 | |
| 2024-09-30 | 12 | $38.0M | 0 | |
| 2024-06-30 | 15 | $232.3M | 0 | |
| 2024-03-31 | 17 | $289.0M | 0 | |
| 2023-12-31 | 16 | $327.5M | 0 |
Takeda Pharmaceutical Co LTD's most significant position changes for 2025-09-30: Sold out: Hillevax INC; Sold out: Turnstone Biologics CORP; Sold out: Third Harmonic Bio INC; Trim: Lyell Immunopharma, Inc. (LYEL) — shares +33.33%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | OVID | Ovid Therapeutics INC | +45.3% | — | Unchanged |
| 2 | EQ | Equillium INC | +11.5% | — | Unchanged |
| 3 | STTK | Shattuck Labs INC | +4.5% | — | Unchanged |
| 4 | LYEL | Lyell Immunopharma, Inc. | +2.7% | +33.33% | Trim |
| 5 | ✓ | Xilio Therapeutics INC | +1% | — | Unchanged |
| 6 | LAB | Standard Biotools INC | 0% | — | Unchanged |
| 7 | AMWL | American Well Corp-class A | -0.9% | — | Unchanged |
| 8 | RANI | Rani Therapeutics Holdings-a | -1% | — | Unchanged |
| 9 | ✓ | Hillevax INC | — | EXIT | Sold out |
| 10 | ✓ | Turnstone Biologics CORP | — | EXIT | Sold out |
| 11 | ✓ | Third Harmonic Bio INC | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2025-09-30 | 2025-11-13 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-08 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-12 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-12 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2025-02-13 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2025-02-13 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2025-02-13 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2025-02-13 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001519921
Total reported value
$16.4M
239 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0000080835
Total reported value
$16.3M
47 stks
2015-06-30
Stale — no recent filing
AUM within 0.2% of this institution
CIK 0001720745
Total reported value
$16.3M
7 stks
2022-03-31
Stale — no recent filing
AUM within 0.3% of this institution
Institutions with overlapping top holdings
CIK 0001730494
Total reported value
$259.9M
16 stks
2022-09-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Lyell Immunopharma, Inc.
CIK 0001812549
Total reported value
$6.8M
3 stks
2024-09-30
Stale — no recent filing
1 of the top 5 holdings overlap
CIK 0001822947
Total reported value
$123.8M
28 stks
2026-03-31
1 of the top 5 holdings overlap, including Ovid Therapeutics INC